IRIDEX (US:IRIX)2022-03-11 03:57Financial Data and Key Metrics Changes - Total revenue for Q4 2021 was $15.3 million, up 24% from $12.3 million in Q4 2020, and total revenue for the full year increased 48% to $53.9 million from $36.4 million in 2020 [24][25] - Gross profit for Q4 was $6 million, an 8% increase from the same period last year, with a gross margin percentage of 39.3%, down from 45.4% in Q4 2020 [29] - Net loss for Q4 2021 was $2.4 million or $0.15 per share, compared to a loss of $0.01 per share for the same period in 2020 [31] Business Line Data and Key Metrics Changes - Cyclo G6 probe sales increased 13% year-over-year, with 15,200 units sold in Q4 2021 [25][12] - Retina product revenue improved significantly in Q4 to $9.1 million, a 31% increase compared to the prior year period, with PASCAL revenue contributing $1.6 million [26][27] - Total glaucoma product revenue for 2021 was $13.9 million, up 23% from 2020, while total retina revenue grew 72% year-over-year [26][27] Market Data and Key Metrics Changes - The company expects Cyclo G6 probe unit sales of 67,000 to 70,000 in 2022, representing approximately 18% growth at the midpoint [20] - The installed base of Cyclo G6 systems is expected to expand by 225 to 250 units in 2022 [21] - The company anticipates total revenue for 2022 to be between $57 million and $59 million [33] Company Strategy and Development Direction - The company aims to accelerate momentum gained in 2021 by supporting its global commercial team with increased clinical data and education programs [18] - Focus areas include expanding market penetration in the U.S. and internationally, particularly in China, and enhancing product development investments [19] - The company plans to leverage revenue growth to expand investments while maintaining a secure capital position [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply chain challenges and anticipates solid growth as capacity limits are lifted [22] - The company believes it can achieve growth rates of 20% to 30% as it matures various growth levers in the glaucoma market [41] - Management highlighted the opportunity to capture significant penetration into the moderate stage glaucoma patient population, estimating a potential for several hundred thousand procedures [44] Other Important Information - The company ended the year with cash and cash equivalents of $23.9 million, an increase of $12.2 million from the end of 2020, primarily due to the Topcon transaction [32] - Operating expenses for Q4 were $8.4 million, reflecting increased R&D spending and planned increases in sales and marketing activities [30] Q&A Session Summary Question: What are the important drivers for Cyclo G6 probe growth in 2022? - Management identified several growth areas, including moving clinicians to treat moderate-stage patients and increasing the number of users at existing sites [35][36] Question: What is the growth aspiration for the G6 business long-term? - Management believes the G6 business can achieve consistent growth of 20% or more as it penetrates the moderate-stage patient market [41] Question: Can you provide insights on the retina business for 2022? - Management indicated that while the retina market is relatively mature, they expect to gain market share and introduce new platforms later in the year [47][49] Question: What should be expected regarding gross margin for 2022? - Management anticipates gross margins in the mid-40s, with potential fluctuations based on revenue and product mix [51][52] Question: How is pricing expected to impact revenue in 2022? - Management noted that while there are pressures on costs, they expect to implement price increases to preserve margins, but competition will play a significant role [53][54]